1. Acknowledgement to Referees

   Acknowledgement to referees 23 November 2020 Pages: 1875 - 1879

2. Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen

   • Andrew Mujugira
   • Jared M. Baeten
   • Jessica E. Haberer

   Current Opinion 10 October 2020 Pages: 1881 - 1888

   

3. A Narrative Review of Aspirin Resistance in VTE Prophylaxis for Orthopaedic Surgery

   • Nameer van Oosterom
   • Michael Barras
   • Neil Cottrell

   Review Article 09 October 2020 Pages: 1889 - 1899

   

4. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review

   • Kottil Rammohan
   • Patricia K. Coyle
   • Thomas P. Leist

   Review Article Open access 28 November 2020 Pages: 1901 - 1928

   

5. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review

   • Fabrizio Cantini
   • Delia Goletti
   • Rosario Foti

   Systematic Review 17 October 2020 Pages: 1929 - 1946

   

6. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon

   • C. Beaudart
   • L. Lengelé
   • J. Y. Reginster

   Systematic Review Open access 19 October 2020 Pages: 1947 - 1959

   

7. Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity

   • Kueiyu Joshua Lin
   • Sebastian Schneeweiss
   • Joshua J. Gagne

   Original Research Article 05 November 2020 Pages: 1961 - 1972

   

8. Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia

   • Hannah A. Blair

   Adis Drug Evaluation 17 November 2020 Pages: 1973 - 1980

9. Sofpironium Bromide: First Approval

   • Julia Paik

   AdisInsight Report 24 November 2020 Pages: 1981 - 1986

   

10. Filgotinib: First Approval

    • Sohita Dhillon
    • Susan J. Keam

    AdisInsight Report Open access 25 November 2020 Pages: 1987 - 1997

    

11. Correction to: Ripretinib: First Approval

    • Sohita Dhillon

    Correction Open access 06 November 2020 Pages: 1999 - 1999

12. Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer

    • Katherine A. Lyseng-Williamson

    Correction 13 November 2020 Pages: 2001 - 2001